Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 3/20 | 0.44 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.43 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | CALCR | P30988 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10066227 | 0.95 | CAPN1 (0.46) | CAPN1NTSR1NTSR2NPY1RNPY2R | |
| SCHEMBL12985549 | 0.94 | CAPN1 (0.46) | CAPN1NTSR1NTSR2TASP1NPY1R | |
| SCHEMBL30872266 | 0.83 | CAPN1 (0.47) | CAPN1NTSR1NTSR2TASP1NPY1R | |
| SCHEMBL31688307 | 0.82 | CALCR (0.49) | CAPN1NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL30185038 | 0.82 | XIAP (0.51) | CAPN1NTSR1NTSR2TASP1NPY1R | |
| SCHEMBL30872268 | 0.81 | CAPN1 (0.46) | CAPN1NTSR1CXCL8 | |
| SCHEMBL12984785 | 0.81 | CAPN1 (0.43) | CAPN1NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL31688350 | 0.81 | CALCR (0.50) | CAPN1NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL30185029 | 0.80 | NTSR1 (0.45) | CAPN1NTSR1CXCL8 | |
| SCHEMBL30872272 | 0.80 | CAPN1 (0.49) | CAPN1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | BRACCO IMAGING S.P.A. (IT) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | TAGLN2, TTN, TXLNA | CAPN1 2006/4885NTSR1 3820/4885NTSR2 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.